ITM Isotope Technologies Prepares for Upcoming Investor Conferences
ITM Isotope Technologies Munich SE (ITM), a key player in the radiopharmaceutical biotech industry, is set to participate in two notable investor conferences in New York City. This move illustrates ITM's dedication to furthering targeted therapies in oncology.
Details on Conference Participation
These upcoming conferences will provide an opportunity for ITM’s Chief Executive Officer, Dr. Andrew Cavey, to share important insights about the company’s innovative pipeline and future plans in the radiopharmaceutical sector.
Redburn Atlantic and Rothschild & Co Conference
The first event will take place on September 26, when Dr. Cavey will present at 12:45 PM ET. During his presentation, he will outline ITM's strategic objectives and discuss the progress made in their targeted therapies.
Oppenheimer Oncology Summit
On October 8, Dr. Cavey will take part in the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit. He will be part of an esteemed panel starting at 8:40 AM ET to explore "PSMA & Prostate Cancer: Opportunities and Challenges for the Next Generation of Targeted Radiopharmaceutical Therapies (TRTs) Post-Pluvicto Success." This discussion is anticipated to illuminate both the difficulties and potential solutions related to prostate cancer, especially in the context of recent advancements.
Corporate Vision and Future Goals
ITM plans to offer vital insights into its groundbreaking work in radiopharmaceuticals, emphasizing its extensive pipeline, which includes two Phase III studies. The company is focused on combining high-quality radioisotopes with varied targeting molecules to improve treatment options for oncology patients around the world. With their broad industry expertise, ITM is devoted to enhancing clinical outcomes and the quality of life for those battling cancer.
Contact Information for Inquiries
For any further questions, stakeholders can reach out to the Investor Relations team. Ben Orzelek is available at +49 89 329 8986 1009 or by emailing investors@itm-radiopharma.com. Additionally, for media inquiries, Kathleen Noonan and Julia Westermeir can be contacted at +49 89 329 8986 1500 or via email at communications@itm-radiopharma.com.
About ITM Isotope Technologies Munich SE
ITM is pioneering advancements in radiomolecular precision therapeutics and diagnostics, particularly targeting difficult-to-treat tumors. The company is committed to improving patient outcomes through a strong pipeline of targeted therapies and its capabilities in radiopharmaceutical development and production. ITM strives to provide effective solutions that cater to the diverse needs of cancer patients and healthcare providers worldwide, supported by its global expertise and network.
Frequently Asked Questions
What does ITM Isotope Technologies specialize in?
ITM Isotope Technologies Munich SE focuses on radiopharmaceuticals and seeks to develop targeted treatments and diagnostics for challenging cancers.
When are the upcoming investor conferences happening?
The conferences are set for September 26 and October 8, featuring presentations by CEO Dr. Andrew Cavey.
What will Dr. Cavey discuss at the investor conferences?
Dr. Cavey will talk about the company’s pipeline in targeted therapies and engage in discussions about advancements in the treatment of prostate cancer.
Who should I reach out to for more details about ITM?
You can contact Ben Orzelek for investor-related inquiries or Kathleen Noonan and Julia Westermeir for media inquiries.
Where can I get more information about ITM's offerings?
For detailed information about their radiopharmaceutical products and ongoing research, please visit their official website.
